Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide. In clinical studies, Sugammadex Injection demonstrated faster recovery compared to neostigmine and was associated with fewer adverse events in clinical studies.2
“With the launch of Sugammadex Injection, B. Braun is continuing to expand our portfolio of essential injectable medications used in acute care settings,” said Jeremy Greene, Senior Director, Pharma Marketing. “This AP-rated generic option provides healthcare systems with an affordable solution and reliable supply of a critical anesthesia reversal agent. The addition helps us continue supporting hospitals and providers in delivering patient care.”